Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Rambaldi A, Ritchie EK, Papayannidis C, Tuglus CA, Morris JD, Stein A. Martinelli G, et al. Among authors: tuglus ca. Eur J Cancer. 2021 Mar;146:107-114. doi: 10.1016/j.ejca.2020.12.022. Epub 2021 Feb 13. Eur J Cancer. 2021. PMID: 33588145 Free article. Clinical Trial.
Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
Gökbuget N, Dombret H, Giebel S, Brüggemann M, Doubek M, Foa R, Hoelzer D, Kim C, Martinelli G, Parovichnikova E, Maria Ribera J, Schoonen M, Tuglus C, Zugmaier G, Bassan R. Gökbuget N, et al. Eur J Haematol. 2020 Apr;104(4):299-309. doi: 10.1111/ejh.13375. Epub 2020 Jan 24. Eur J Haematol. 2020. PMID: 31876009 Free PMC article.
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Rambaldi A, Ribera JM, Kantarjian HM, Dombret H, Ottmann OG, Stein AS, Tuglus CA, Zhao X, Kim C, Martinelli G. Rambaldi A, et al. Among authors: tuglus ca. Cancer. 2020 Jan 15;126(2):304-310. doi: 10.1002/cncr.32558. Epub 2019 Oct 18. Cancer. 2020. PMID: 31626339 Free PMC article. Clinical Trial.
Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
Kiyoi H, Morris JD, Oh I, Maeda Y, Minami H, Miyamoto T, Sakura T, Iida H, Tuglus CA, Chen Y, Dos Santos C, Kalabus J, Anderson A, Hata T, Nakashima Y, Kobayashi Y. Kiyoi H, et al. Among authors: tuglus ca. Cancer Sci. 2020 Apr;111(4):1314-1323. doi: 10.1111/cas.14322. Epub 2020 Feb 11. Cancer Sci. 2020. PMID: 31971321 Free PMC article. Clinical Trial.
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, Heym KM, Katz AJ, Kelsh MA, Sposto R, Tu H, Tuglus CA, Verma A, Vinti L, Wilkes JJ, Zubarovskaja N, Zugmaier G, von Stackelberg A, Sun W. Locatelli F, et al. Among authors: tuglus ca. Leukemia. 2020 Sep;34(9):2473-2478. doi: 10.1038/s41375-020-0770-8. Epub 2020 Feb 24. Leukemia. 2020. PMID: 32094465 Free PMC article. No abstract available.
11 results